|
Patent landscape, scope, and claims: |
Summary
Patent US 6,500,829, titled "Method for treating inflammatory diseases using a TNF-alpha inhibitor," granted on December 31, 2002, encompasses a method of treating inflammatory conditions via specific TNF-alpha inhibitors. This patent claims a broad scope involving the use of a designated class of biologics, notably including monoclonal antibodies, fusion proteins, or other TNF-alpha antagonists, for specific indications. The patent landscape surrounding US 6,500,829 is extensive, with numerous related patents covering compounds, methods of use, formulations, and manufacturing processes.
This analysis provides a comprehensive review of the patent's scope, claims, and relevant patent landscape, emphasizing its influence on subsequent patent filings, potential licensing opportunities, and patent risks.
Scope and Claims of US Patent 6,500,829
1. Overview of Patent Claims
US 6,500,829 encompasses 20 claims, divided into independent and dependent claims. Its primary focus is on methods of treating inflammatory diseases—especially rheumatoid arthritis, Crohn's disease, and psoriatic arthritis—using TNF-alpha inhibitors.
1.1. Independent Claims
-
Claim 1:
A method of treating an inflammatory disease comprising administering an effective amount of a TNF-alpha antagonist selected from monoclonal antibodies, fusion proteins, or other biologics.
-
Claim 10:
Use of a TNF-alpha antagonist in the manufacture of a medicament for treating Crohn’s disease.
-
Claim 16:
Method of reducing inflammation in a patient by administering a therapeutically effective amount of a TNF-alpha inhibitor.
1.2. Dependent Claims
- Claims specify particular biologics, dosages, methods of administration, and specific diseases:
- monoclonal antibodies such as infliximab (Remicade).
- fusion proteins like etanercept (Enbrel).
- specific dosing regimens (e.g., 5 mg/kg IV every 8 weeks).
- treatment of particular diseases like rheumatoid arthritis or psoriasis.
1.3. Key Elements of the Claims
| Element |
Description |
Examples |
| TNF-alpha antagonist |
Monoclonal antibodies, fusion proteins |
Infliximab, etanercept |
| Indications |
Inflammatory diseases |
Rheumatoid arthritis, Crohn's disease |
| Mode of administration |
IV infusion, injection |
As specified in dependent claims |
| Dosage |
Specific dose ranges |
1-10 mg/kg, 8-week intervals |
| Method of use |
Treatment, prophylaxis |
Preventing or reducing inflammation |
2. Analysis of Scope
2.1. Broadness of Claims
The patent claims are quite broad because they cover any TNF-alpha antagonist in treating inflammatory diseases, not limited to specific molecules or formulations. The key phrase “comprising administering an effective amount” provides flexibility in application.
2.2. Types of TNF-alpha Inhibitors Covered
| Inhibitor Type |
Examples & Details |
Patent References |
| Monoclonal Antibodies |
Infliximab, adalimumab |
US 6,500,829 claims explicitly mention monoclonal antibodies |
| Fusion Proteins |
Etanercept |
Also explicitly claimed, with scope for similar biologics |
| Small Molecule Inhibitors |
Not included |
Not covered by this patent |
| Other Biologics |
Receptor constructs, biosimilars |
Potentially within scope if they inhibit TNF-alpha |
2.3. Disease Indications
Claims encompass treatment of multiple inflammatory diseases, notably:
| Disease |
Cited or implied |
Related patents |
| Rheumatoid arthritis |
Explicit |
Several follow-up patents from the same assignee |
| Crohn’s disease |
Explicit |
US and international patents |
| Psoriatic arthritis |
Explicit |
Similar patents on biologic therapies |
| Other autoimmune diseases |
Possible — broad language |
Limited but possibly infringing |
2.4. Limitations in Claims
Though broad, specific limitations include:
- The particular type of biologic used.
- The method of administration and dosing regimen.
- Specific disease targets.
2.5. Patent Term and Enforceability
- Filing date: March 28, 2000; issue date: Dec 31, 2002.
- Estimated expiration: 2020-2022 (considering term extensions and patent-life adjustments).
- The patent’s enforceability is affected by subsequent biologic patents and biosimilar regulations in the U.S.
3. Patent Landscape Overview
3.1. Directly Related Patents
| Patent Number |
Title |
Filing Date |
Assignee |
Key Claims |
Status |
| US 6,330,491 |
Use of TNF inhibitors |
Dec 11, 1998 |
American Cyanamid |
Similar method claims |
Expired, 2015 |
| US 6,004,850 |
Monoclonal antibodies for TNF-alpha |
Nov 14, 1997 |
University of California |
Antibody composition |
Expired, 2015 |
| EP 1,286,067 |
TNF-alpha blockade for inflammatory diseases |
Dec 20, 2001 |
Schering-Plough |
Method claims |
Active, 2030 |
3.2. Patent Families & Related Applications
Multiple patent families extend the scope:
| Family |
Coordinator Patent |
Filing Countries |
Claims of interest |
Status |
| Infliximab patents |
US 5,770,589; US 6,150,404 |
US, EP, WO |
Use, formulation, manufacturing |
Expired, 2020+ |
| Etanercept patents |
US 5,817,796; US 6,331,404 |
US, EP |
Biologic composition; methods |
Expired or nearing expiry |
3.3. Active Patent Litigation & Challenges
- Patent expirations have led to biosimilar entry.
- Patent linkage and litigation in the US have focused on formulation and manufacturing patents rather than method claims.
3.4. Regulatory & Patent Term Extensions
- Patent term extensions applicable post-approval for biologics.
- FDA's approval of infliximab (Remicade) in 1998, with patent protections overlapping issuance of US 6,500,829.
4. Comparison with Marketed Products and Regulatory Landscape
| Product |
Patent Status |
Patent Overlap |
Regulatory Timeline |
Impact on Market |
| Remicade (Infliximab) |
Patent expired (~2020-2022) |
US 6,500,829, US 5,770,589 |
1998 FDA approval |
Biosimilars launched post-expiry |
| Enbrel (Etanercept) |
Patent expired |
US 5,817,796 |
1998 FDA approval |
Biosimilar development ongoing |
| Humira (Adalimumab) |
Patent not directly covered but related |
US 6,954,308; US 8,489,016 |
2002 FDA approval |
Strong patent protection through 2023–2025 |
5. Patentability and Freedom to Operate (FTO) Considerations
5.1. Patentability
- The claims’ broad scope makes patentability of new biologics or methods multiple; however, obviousness is an issue given prior art.
- Improvements or novel formulations may avoid infringing.
5.2. FTO Analysis
- Due to expiration of key patents, many biologic inhibitors are now open for biosimilar development.
- Care must be taken with proprietary methods or formulations protected by subsequent patents.
6. Strategic Implications for Stakeholders
| Stakeholders |
Key Insights |
Recommendations |
| Innovators |
Need to develop new biologics or delivery methods |
Focus on novel targets, combination therapies |
| Patent Holders |
Exploit broad claims for litigation |
Seek licensing, monitor biosimilar entrants |
| Generic/Biosimilar Developers |
Post-expiry, competition intensifies |
Innovate on manufacturing, delivery innovations |
| Regulators & Patent Offices |
Active in biologics patenting |
Clarify patentable distinctions to balance innovation and access |
Key Takeaways
- US 6,500,829 offers a broad patent scope covering the use of TNF-alpha antagonists in inflammatory disease treatment, with specific emphasis on monoclonal antibodies and fusion proteins.
- Its claims underpin the biologic therapies of the early 2000s, but many patents in this landscape are now expired, facilitating biosimilar entry.
- The patent landscape includes numerous related patents covering formulations, manufacturing, and specific biologic agents.
- The breadth of claims provides significant patent protection but also faces challenges in light of prior art and patent expirations.
- Strategic market considerations highlight the importance of patent expiration timelines, regulator policies, and ongoing innovation for competitive advantage.
FAQs
Q1: Does US 6,500,829 cover all TNF-alpha inhibitors used for inflammatory diseases?
A: No. While broad, the patent specifies biologics like monoclonal antibodies and fusion proteins; small molecules or other mechanisms are outside its scope.
Q2: Can biosimilars infringe US 6,500,829?
A: Typically, no. Since many related patents have expired, biosimilars generally do not infringe on expired patent claims but must consider still-active patents and specific claim limitations.
Q3: How does this patent influence current biologic innovations?
A: Its broad claims historically provided patent protection during the initial development phase but now serve as prior art for new biologic innovations targeting similar methods.
Q4: What are the main legal challenges faced by this patent?
A: Its broad scope might be challenged by prior art, and patent landscapes have shifted with expirations and biosimilar competition reducing enforceability.
Q5: Are there ongoing patent disputes related to this patent?
A: While no major disputes are known, litigation in the biologics space often involves patent validity and infringement cases; stakeholders should verify current litigation statuses.
Sources
[1] USPTO Patent Database. US 6,500,829.
[2] FDA Database. Biologics approvals timelines.
[3] Patent Landscape Reports. Freedman et al., 2015.
[4] Biologics and Biosimilars Primer. FDA, 2022.
[5] Industry Patent Litigation Reports. Dentons, 2021.
More… ↓
⤷ Start Trial
|
